ClinicalTrials.gg

Program

arcotatug tavatecan

Also written as “IBI343”, “IBI343,Gemcitabine, Albumin-bound Paclitaxel” and “IBI343,sintilimab,oxaliplatin,S-1”.

Its studies are mostly in Pancreatic Neoplasms, led by Innovent Biologics.

Furthest: phase 3, since Jan 25, 20245 company-led studies, 5 open or runningNext primary completion: Dec 30, 2026 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Innovent Biologics55 open or runningphase 3since Jan 25, 2024Jul 11, 2022Dec 30, 2026phase 3 · NCT06238843

Also a collaborator on its studies: TigerMed.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 11, 2022First study: phase 1 study in Locally Advanced Unresectable or Metastatic Solid TumorsFirst studyNCT05458219 · 470 planned · United States, Australia, China
  2. Jan 25, 2024Phase 3 study in Unresectable or Metastatic Gastric or Gastroesophageal Junction AdenocarcinomaNCT06238843 · 464 enrolled · China, Japan
  3. Jun 26, 2025Phase 3 study in Pancreatic NeoplasmsNCT07066098 · 201 planned · China
  4. Mar 16, 20262 phase 2 studies in CLDN18.2 PositiveNCT07483567, NCT07483554

Ahead

  1. Dec 30, 2026Primary completion: phase 3 study in Unresectable or Metastatic Gastric or Gastroesophageal Junction AdenocarcinomaNCT06238843
  2. Jun 30, 2027Primary completion: phase 3 study in Pancreatic NeoplasmsNCT07066098
  3. Jun 30, 2027Primary completion: phase 1 study in Locally Advanced Unresectable or Metastatic Solid TumorsNCT05458219
  4. Mar 31, 2028Primary completion: phase 2 study in CLDN18.2 PositiveNCT07483554

TargetBeta

CLDN18 →read by rule
“An antibody-drug conjugate (ADC) composed of arcotatug, a Fc-silenced humanized immunoglobulin G1 (IgG1) monoclonal antibody directed against the tumor-associated antigen (TAA) Claudin18.2 (CLDN18.2; A2 isoform of claudin-18), ”NCIt, by rule

Other programs on CLDN18

ProgramCompanyFurthest phaseStudies
zolbetuximabruleAstellas Pharmaphase 412
sonesitatug vedotinAstraZenecaphase 37
garetatug rezetecanJiangsu HengRui Medicinephase 37
Anti-Claudin18.2/Anti-CD3 Bispecific Antibody QLS31905ruleQilu Pharmaceuticalphase 36
tecotabart vedotinSino Biopharmaceuticalphase 36
terallethrinruleFutureGen Biopharmaceutical (Beijing)phase 33
Anti-Claudin 18.2 Antibody-drug Conjugate BL-M05D1biokin-shanghai-biopharmaceutical-co-ltdphase 33
emaretamigruleAstellas Pharmaphase 33
Anti-Claudin 18.2 Antibody-drug Conjugate MK-1200ruleSichuan Kelun Pharmaceuticalphase 23
Anti-Claudin 18.2 Antibody-drug Conjugate ASP546CruleAstellas Pharmaphase 22
givastomigrulei-mab-biopharma-us-limitedphase 22
Anti-Claudin18.2/Anti-CD3 Bispecific Antibody AZD5863AstraZenecaphase 21

Studies

All 5 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07483567CLDN18.2 Positive · China2RecruitingJun 30, 203090
NCT07483554CLDN18.2 Positive · China2RecruitingMar 31, 2028389
NCT07066098Pancreatic Neoplasms · China3RecruitingJun 30, 2027201
NCT06238843Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma · China, Japan3Active, not recruitingDec 30, 2026464
NCT05458219Locally Advanced Unresectable or Metastatic Solid Tumors · United States, Australia, China1RecruitingJun 30, 2027470

How it is read

Names in the registry

  • “IBI343”, 4 entries
  • “IBI343,Gemcitabine, Albumin-bound Paclitaxel”, 1 entry
  • “IBI343,sintilimab,oxaliplatin,S-1”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.